MRK · Healthcare

Merck & Co., Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Guidance / OutlookImportance 75 · Surprise 60
  Merck raised its full-year 2026 sales outlook to $66.3 billion-$67.3 billion after second-quarter revenue reached $16.6 billion. The revised sales range reflects stronger demand for KEYTRUDA, Winrevair and other newer…
• Competition and Market ShareImportance 58 · Surprise 42
  Dr. Reddy’s launched first-to-market U.S. generic versions of sugammadex injection, directly competing with Merck’s Bridion. The products are available in 200 mg/2 mL and 500 mg/5 mL single-dose vials and target…
• Revenue Performance and MixImportance 49 · Surprise 32
  Merck reported second-quarter 2026 worldwide sales of $16.61 billion, up 5.1% year over year and 4% excluding foreign exchange. KEYTRUDA family sales increased 4% to $8.4 billion, while Winrevair sales rose 75% to $588…
• Geographic Market CommentaryImportance 23 · Surprise 42
  Merck’s Ervebo Ebola vaccine is being deployed more broadly in response to a worsening outbreak in eastern Democratic Republic of Congo. The outbreak involves the Bundibugyo strain and has produced nearly 4,000 cases…
• India Litigation JurisdictionImportance 21 · Surprise 42
  The U.S. Court of Appeals for the Third Circuit ruled that a contract dispute involving Merck and a now-defunct Indian pharmaceutical company must be litigated in India. The dispute concerns a terminated business…

10-Q · 2026-08-07

• Competition and Pricing PressureImportance 78 · Surprise 74
  Competitive pressure and loss of exclusivity materially reduced sales of Januvia/Janumet, Dificid, and Lagevrio, while generic competition also weakened international Bridion demand and contributed to Vaxneuvance…
• Liquidity and Debt PositionImportance 76 · Surprise 56
  Cash and investments declined to $8.363 billion at June 30, 2026 from $15.521 billion at December 31, 2025, while working capital declined to $8.948 billion from $15.189 billion. Operating cash flow increased to $9.3…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Merck acquired TARGAN in July 2026 for approximately $650 million to expand Merck Animal Health’s poultry portfolio with WingScan automated gender identification and precision ocular spray technology. Merck acquired…
• Acquisitions and DivestituresImportance 71 · Surprise 60
  Merck recorded significant business-development charges of $5.7 billion for the Terns acquisition and $9.0 billion for the Cidara acquisition during the first six months of 2026. The Terns transaction involved…
• Outstanding IndebtednessImportance 66 · Surprise 48
  Merck drew the full $6.0 billion available under a 364-day delayed-draw term loan facility in April 2026 to fund part of the approximately $6.8 billion cash consideration for Terns, and subsequently repaid the…
• Income Tax Rate ChangesImportance 65 · Surprise 82
  Merck reported a $654 million income tax provision on a $683 million pretax loss in the second quarter of 2026, producing a negative 95.9% effective tax rate. The Terns acquisition charge created a 108.9…
• Headcount / RestructuringImportance 64 · Surprise 42
  Merck’s 2025 Restructuring Program will eliminate selected sales, administrative, and R&D positions, reduce the global real-estate footprint, and optimize the manufacturing network. The program is expected to be…
• Clinical Pipeline DevelopmentsImportance 61 · Surprise 42
  Tulisokibart met the primary endpoint of clinical remission in the Phase 3 ATLAS-UC induction-only study in patients with moderately to severely active ulcerative colitis and also met key secondary endpoints. A Phase 2…
• Gross Margin DriversImportance 59 · Surprise 48
  Gross margin declined to 73.5% in the second quarter of 2026 from 77.5% in the prior-year quarter and to 73.9% from 77.7% for the first six months. Cost of sales increased 24% in the quarter and 23% year to date,…
• Research and Development ExpenseImportance 58 · Surprise 42
  R&D expense increased in 2026 because of higher clinical development spending, unfavorable foreign exchange, and $14.7 billion of Terns and Cidara acquisition charges across the first six months. Merck’s direct Merck…
• Single-Dose HPV Vaccine ResearchImportance 58 · Surprise 42
  Merck is collaborating with the U.S. National Cancer Institute and Agencia Costarricense de Investigaciones Biomédicas to extend the Costa Rica ESCUDDO trial evaluating a single HPV vaccine dose in females ages 12 to…
• Guidance and OutlookImportance 57 · Surprise 50
  Merck expects alliance revenue to decline for full-year 2026 as Adempas loses U.S. market exclusivity. The company expects U.S. Bridion sales to decline following loss of market exclusivity in July 2026 and plans to…
• Revenue Performance and MixImportance 49 · Surprise 32
  Worldwide sales increased 5% year over year to $16.6 billion in the second quarter of 2026 and to $32.9 billion in the first six months of 2026. U.S. sales rose to $9.4 billion in the quarter and $18.5 billion year to…
• Operating Expense TrendsImportance 47 · Surprise 22
  SG&A expense increased 10% year over year in the second quarter of 2026 to $2.9 billion and 8% in the first six months to $5.6 billion. Higher administrative costs, including IT investments, increased promotional and…
• Vaccine Policy LitigationImportance 47 · Surprise 60
  In January 2026, the acting CDC director changed the child and adolescent immunization schedule, reducing routinely recommended vaccinations and creating categories for universal, high-risk and shared-clinical-decision…
• Regulatory RiskImportance 44 · Surprise 60
  The FDA’s emergency-use framework for COVID-19 products is being terminated following the HHS Secretary’s June 29, 2026 determination that pandemic circumstances no longer justify emergency use. Lagevrio’s U.S. EUA is…
• Capital Return ProgramImportance 42 · Surprise 14
  Merck paid $4.2 billion of dividends to stockholders in the first six months of 2026, up from $4.1 billion in the prior-year period. The Board declared quarterly dividends of $0.85 per share for the second and third…
• Pricing and Market AccessImportance 40 · Surprise 42
  Merck reported worldwide pricing pressure from health-care cost containment, including U.S. Medicaid rebates, increased 340B utilization, and Medicare price-setting under the Inflation Reduction Act. Government-set…
• Geographic Market CommentaryImportance 40 · Surprise 42
  U.S. demand was strong for Keytruda/Keytruda Qlex, Welireg, Winrevair, and Prevymis, but U.S. vaccine demand weakened and Januvia/Janumet faced competitive volume declines. Gardasil/Gardasil 9 demand grew in Europe and…
• German Health-Care ReformImportance 40 · Surprise 42
  Germany’s parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG) in July 2026. Most provisions take effect January 1, 2027 and introduce cost-containment measures intended…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Under its December 2025 three-year most-favored-nation (MFN) agreement with the U.S. government, Merck provides Januvia, Janumet and Janumet XR through a direct-to-patient program and plans to expand it to Lipfendra.…
• Manufacturing Network OptimizationImportance 37 · Surprise 42
  Merck is optimizing its global Human Health manufacturing network as its pipeline shifts toward new modalities and is also optimizing the Animal Health network to improve supply reliability and efficiency. The 2025…
• Oncology Trial DiscontinuationImportance 37 · Surprise 42
  Merck and Gilead Sciences are discontinuing the Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy combined with Keytruda versus Keytruda monotherapy in previously untreated metastatic non-small-cell lung cancer with PD-L1…
• Lagevrio U.S. Market TransitionImportance 37 · Surprise 42
  Lagevrio remains available in the U.S. under an Emergency Use Authorization for certain adults with mild to moderate COVID-19 who are at risk of progressing to severe disease. The U.S. EUA is scheduled to terminate on…
• Animal Health DemandImportance 36 · Surprise 40
  Livestock product sales grew 8% in the second quarter and 12% in the first six months of 2026, primarily from higher ruminant and poultry demand. Companion animal sales increased 7% and 8%, respectively, supported by…
• Products and TechnologyImportance 31 · Surprise 42
  Merck expanded its product portfolio through new formulations, indications, and launches including Keytruda Qlex/Keytruda SC, Capvaxive, Enflonsia, Lipfendra, Idvynso, and Numelvi. Keytruda and Keytruda Qlex received…
• Supply Chain and InventoryImportance 26 · Surprise 24
  Gardasil/Gardasil 9 shipments to China were suspended in February 2025 because of lower demand and elevated channel inventory, with only limited shipments restarting in the second quarter of 2026. Enflonsia sales…
• Regulatory Pipeline ProgressImportance 23 · Surprise 24
  Merck reported multiple products under regulatory review in the U.S., EU, Japan, and China as of August 5, 2026. FDA PDUFA target dates include October 10, 2026, for I-DXd in previously treated extensive-stage…

News · 2026-08-07

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Merck recorded a $5.7 billion charge related to its acquisition of Terns Pharmaceuticals in the second quarter of 2026. The charge reduced GAAP diluted earnings per share by $2.31 and contributed to a GAAP net loss of…
• Revenue Performance and MixImportance 49 · Surprise 32
  Merck reported second-quarter 2026 worldwide sales of $16.61 billion, up 5.1% year over year and 4% excluding foreign exchange. KEYTRUDA family sales increased 4% to $8.4 billion, while Winrevair sales rose 75% to $588…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Merck advanced sac-TMT, an antibody-drug conjugate targeting Trop-2, into multiple Phase 3 cancer trials. The program is positioned as a potential future lung-cancer treatment and supports Merck’s effort to build…
• Geographic Market CommentaryImportance 23 · Surprise 42
  Merck’s Ervebo Ebola vaccine is being deployed more broadly in response to a worsening outbreak in eastern Democratic Republic of Congo. The outbreak involves the Bundibugyo strain and has produced nearly 4,000 cases…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Merck declared a quarterly dividend of $0.85 per share in connection with its second-quarter 2026 reporting. The dividend provides an annualized cash distribution of $3.40 per share if maintained for four quarters.…

News · 2026-08-06

• Guidance / OutlookImportance 75 · Surprise 60
  Merck raised its full-year 2026 sales outlook to $66.3 billion-$67.3 billion after second-quarter revenue reached $16.6 billion. The revised sales range reflects stronger demand for KEYTRUDA, Winrevair and other newer…
• Revenue Performance and MixImportance 49 · Surprise 32
  Merck reported second-quarter 2026 worldwide sales of $16.61 billion, up 5.1% year over year and 4% excluding foreign exchange. KEYTRUDA family sales increased 4% to $8.4 billion, while Winrevair sales rose 75% to $588…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  The U.S. Food and Drug Administration accepted Merck’s supplemental Biologics License Application for ENFLONSIA, also known as clesrovimab-cfor. The application seeks to expand the RSV lower respiratory tract disease…
• Product Launch and TransitionImportance 34 · Surprise 42
  Merck is using newer products to diversify growth ahead of the expected Keytruda loss of exclusivity. LIPFENDRA, an oral PCSK9 inhibitor, received U.S. FDA approval, while Winrevair showed strong commercial uptake. The…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Merck advanced sac-TMT, an antibody-drug conjugate targeting Trop-2, into multiple Phase 3 cancer trials. The program is positioned as a potential future lung-cancer treatment and supports Merck’s effort to build…

News · 2026-08-05

• Guidance / OutlookImportance 75 · Surprise 60
  Merck raised its full-year 2026 sales outlook to $66.3 billion-$67.3 billion after second-quarter revenue reached $16.6 billion. The revised sales range reflects stronger demand for KEYTRUDA, Winrevair and other newer…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Merck recorded a $5.7 billion charge related to its acquisition of Terns Pharmaceuticals in the second quarter of 2026. The charge reduced GAAP diluted earnings per share by $2.31 and contributed to a GAAP net loss of…
• Competition and Market ShareImportance 58 · Surprise 42
  Dr. Reddy’s launched first-to-market U.S. generic versions of sugammadex injection, directly competing with Merck’s Bridion. The products are available in 200 mg/2 mL and 500 mg/5 mL single-dose vials and target…
• Revenue Performance and MixImportance 49 · Surprise 32
  Merck reported second-quarter 2026 worldwide sales of $16.61 billion, up 5.1% year over year and 4% excluding foreign exchange. KEYTRUDA family sales increased 4% to $8.4 billion, while Winrevair sales rose 75% to $588…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Merck advanced sac-TMT, an antibody-drug conjugate targeting Trop-2, into multiple Phase 3 cancer trials. The program is positioned as a potential future lung-cancer treatment and supports Merck’s effort to build…
• Litigation and Legal RiskImportance 31 · Surprise 42
  A shareholder class action alleges that Merck made misleading statements about projected Gardasil revenue in China. The alleged securities-fraud period runs from February 3, 2022, through February 3, 2025. The reported…

8-K · 2026-08-04

• Income Tax Rate ChangesImportance 65 · Surprise 82
  The second-quarter 2026 income tax provision was $654 million despite a pretax loss of $683 million, producing a negative 95.9% effective tax rate versus 11.4% in the second quarter of 2025. The Terns acquisition…
• Product Launch and TransitionImportance 65 · Surprise 82
  KEYTRUDA QLEX generated $463 million in second-quarter sales as the subcutaneous formulation began contributing to the KEYTRUDA franchise. WINREVAIR sales increased 75% to $588 million through continued U.S. uptake and…
• Market Demand TrendsImportance 57 · Surprise 64
  KEYTRUDA/KEYTRUDA QLEX sales increased 5% to $8.366 billion, driven by global uptake in earlier-stage triple-negative breast cancer, cervical, head and neck and bladder cancer indications, as well as metastatic…
• Gross Margin DriversImportance 53 · Surprise 48
  GAAP gross margin declined to 73.5% in the second quarter of 2026 from 77.5% in the second quarter of 2025. Cost of sales increased 24% to $4.395 billion from $3.557 billion. The margin decline was primarily caused by…
• Headcount / RestructuringImportance 53 · Surprise 82
  GAAP restructuring costs were $151 million in the second quarter of 2026, down 73% from $560 million in the second quarter of 2025. First-half 2026 restructuring costs were $346 million, a 45% decrease from $629…
• Revenue Performance and MixImportance 49 · Surprise 32
  Second-quarter 2026 worldwide sales increased 5% year over year to $16.607 billion, or 4% excluding foreign exchange. Pharmaceutical sales rose 5% to $14.760 billion, driven primarily by oncology, cardiometabolic and…
• Competition and Pricing PressureImportance 40 · Surprise 56
  JANUVIA/JANUMET sales declined 31% to $429 million because of lower U.S. demand and net pricing amid competition, along with lower demand in China and most other international markets from ongoing generic competition.…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  The U.S. FDA approved LIPFENDRA (enlicitide) as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia. Merck described it as the first and only once-daily oral PCSK9 inhibitor and based…
• FX / Currency HeadwindsImportance 32 · Surprise 24
  Merck expects foreign exchange to provide a positive contribution to its 2026 outlook rather than a headwind. The company estimates approximately 1% of positive foreign-exchange impact on full-year sales at mid-July…
• Product and Pipeline ProgressImportance 31 · Surprise 42
  Merck received U.S. approvals for KEYTRUDA and KEYTRUDA QLEX combinations with WELIREG in adjuvant clear cell renal cell carcinoma, with Padcev before and after surgery in muscle-invasive bladder cancer, and with…
• Geographic Market CommentaryImportance 17 · Surprise 24
  Demand was stronger for GARDASIL/GARDASIL 9 in Asia Pacific and Europe, with favorable timing of European tenders, although certain other international markets were weaker. WINREVAIR showed early international launch…